Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

105 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Cervical Cancer Registration SWOG S0227 NCT00057928 - Registration Form Cervical Cancer NCT00057928

- 27.09.21 - 1 Formular, 2 Itemgruppen, 29 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient data
Southwest Oncology Group Registration Form (S0227) S0227 Comparison of Cisplatin Combined With Either Paclitaxel or Gemcitabine in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer NCT00057928 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A9C4563A-B1F7-3ACF-E034-0003BA12F5E7

Cervical Cancer Radiation with or without Chemotherapy NCT01101451 GOG-0263 - Lab and Specimen (Form SP)

- 20.09.21 - 1 Formular, 5 Itemgruppen, 50 Datenelemente, 1 Sprache
Itemgruppen: HEADER MODULE, SPECIMEN INFORMATION, BLOOD/FLUID PRODUCTS, TISSUE/CELLS, GOG TISSUE BANK/LABORATORY INFORMATION
Lab - Gynecologic Oncology Group Specimen Form (Form SP) - 2759412v1.0 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery https://clinicaltrials.gov/ct2/show/NCT01101451

RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Initial Evaluation Form (I1) NCT00980954

- 20.09.21 - 1 Formular, 8 Itemgruppen, 79 Datenelemente, 1 Sprache
Itemgruppen: Header Module, Assessment, Histologic Category, HIGH RISK FEATURES, Examinations, Baseline Lab Values, General Conditions, Footer Module
RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Initial Evaluation Form (I1) NCT00980954 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5D016EA3-A43F-2E2A-E044-0003BA3F9857

NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Concurrent Systemic Treatment Summary Form (TF)

- 20.09.21 - 1 Formular, 6 Itemgruppen, 59 Datenelemente, 1 Sprache
Itemgruppen: RTOG clinical trial administrative data, Summary of Systemic Treatment, Treatment Summary, Protocol Specific Adverse Event Evaluation, Lab results, Footer Module
NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Concurrent Systemic Treatment Summary Form (TF) Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5FE95381-CD25-390D-E040-BB89AD436907

NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Adjuvant System Treatment Summary Form (SF)

- 20.09.21 - 1 Formular, 6 Itemgruppen, 61 Datenelemente, 1 Sprache
Itemgruppen: RTOG clinical trial administrative data, Summary of Systemic Treatment, Treatment Summary, Adverse Events, Lab results, Comments
NCT00980954 RTOG 0724 Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy: Adjuvant System Treatment Summary Form (SF) Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5CFDEE98-0544-2FA7-E044-0003BA3F9857

NCT00980954 RTOG 0724 F1: Radiation Therapy Oncology Group Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy Follow-up Form

- 20.09.21 - 1 Formular, 5 Itemgruppen, 38 Datenelemente, 1 Sprache
Itemgruppen: RTOG clinical trial administrative data, Death Assessment, Has Patient Been Diagnosed With A New Progression?, Non-Protocol Therapy, Adverse Events
NCT00980954 RTOG 0724 F1: Radiation Therapy Oncology Group Phase III Cervix Chemo RT (+)/(-) Adjuvant Chemotherapy Follow-up Form Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5C78147E-D46C-4734-E044-0003BA3F9857

GOG-0240: Fast Fact Sheet for Protocol 0240 (Cervix) NCT00803062

- 20.09.21 - 1 Formular, 4 Itemgruppen, 84 Datenelemente, 1 Sprache
Itemgruppen: Patient demographics, Miscellaneous Patient Information, Lab Results, Provide comments about this Fast Fact Sheet
GOG-0240: Fast Fact Sheet for Protocol 0240 (Cervix) NCT00803062 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=79B3F748-B0A4-3597-E040-BB89AD433B56

Cervical Cancer NCT00262821 Lab - Specimen Form, Form SP, GOG-0219 - 2302462v3.0 - Specimen Form, Form SP, GOG-0219

- 17.09.21 - 1 Formular, 7 Itemgruppen, 55 Datenelemente, 1 Sprache
Itemgruppen: HEADER MODULE, SITE CONTACT INFORMATION, GENERAL SPECIMEN INFORMATION, BLOOD/FLUID PRODUCTS, TISSUE/CELLS, GOG TISSUE BANK/LABORATORY INFORMATION, FOOTER MODULE
Specimen Form, Form SP, GOG-0219 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=EF898F9F-93F3-0C07-E034-0003BA3F9857

Cervical Cancer Cisplatin NCT00064077 GOG - Registration Form

- 15.03.21 - 1 Formular, 3 Itemgruppen, 28 Datenelemente, 1 Sprache
Itemgruppen: HEADER MODULE, TRACKING INFORMATION, Demographic Information
GOG Registration Form - 2058698v3.0 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix https://clinicaltrials.gov/ct2/show/NCT00064077

Oral Topotecan Daily x 5 Days vs. Oral Topotacan 5 Days On, 2 Days Off; 104864/502 - CRF Tracking/Review Forms

- 08.07.19 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Administrative documentation, Clinical Trial Regulatory Tracking Document
Study ID: 104864/502 Clinical Study ID: 104864/502 Study Title: An Open-Label, Multicenter, Randomized, Phase II Study of Oral Topotecan Daily x 5 Days vs. Oral Topotecan 5 Days On, 2 Days Off for 3 Weeks for Second-Line Treatment in Patients with Recurrent, Locally Advanced or Metastatic Cervical Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: N/A Study Indication: Cancer, Locally Advanced or Metastatic Cervical Cancer

Oral Topotecan Daily x 5 Days vs. Oral Topotacan 5 Days On, 2 Days Off; 104864/502 - Laboratory Tests

- 08.07.19 - 1 Formular, 4 Itemgruppen, 25 Datenelemente, 1 Sprache
Itemgruppen: Administrative documentation, Laboratory Procedures, Hematology finding, Laboratory Procedures, Blood Chemical Analysis, Laboratory Procedures, Urinalysis
Study ID: 104864/502 Clinical Study ID: 104864/502 Study Title: An Open-Label, Multicenter, Randomized, Phase II Study of Oral Topotecan Daily x 5 Days vs. Oral Topotecan 5 Days On, 2 Days Off for 3 Weeks for Second-Line Treatment in Patients with Recurrent, Locally Advanced or Metastatic Cervical Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: N/A Study Indication: Cancer, Locally Advanced or Metastatic Cervical Cancer

Oral Topotecan Daily x 5 Days vs. Oral Topotacan 5 Days On, 2 Days Off; 104864/502 - Laboratory Tests

- 08.07.19 - 1 Formular, 4 Itemgruppen, 25 Datenelemente, 1 Sprache
Itemgruppen: Administrative documentation, Laboratory Procedures, Hematology finding, Laboratory Procedures, Blood Chemical Analysis, Laboratory Procedures, Urinalysis
Study ID: 104864/502 Clinical Study ID: 104864/502 Study Title: An Open-Label, Multicenter, Randomized, Phase II Study of Oral Topotecan Daily x 5 Days vs. Oral Topotecan 5 Days On, 2 Days Off for 3 Weeks for Second-Line Treatment in Patients with Recurrent, Locally Advanced or Metastatic Cervical Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: N/A Study Indication: Cancer, Locally Advanced or Metastatic Cervical Cancer

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video